Stocktoria

Contineum Therapeutics, Inc. CTNM

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2024-04-05

Contineum Therapeutics, Inc. statistics & valuation

Market cap$530.5M
P / B2.0×
Return on equity-23.0%
Return on capital-25.5%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202320242025
Operating margin (%)
32.20% 202320242025
Return on equity (%)
-21.30% -23.00% 202320242025
Shares outstanding
3.4M 19.4M 27.7M 202320242025
Net debt ($)
202320242025
Share buybacks ($)
202320242025
Return on assets (%)
17.40% -19.90% -21.70% 202320242025
Free cash flow margin (%)
37.90% 202320242025
Debt / equity (×)
202320242025
EPS ($)
$0.08 -$2.18 -$2.17 202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023
Operating margin——32.2%
Net margin——45.4%
FCF margin——37.9%
Return on assets-21.7%-19.9%17.4%
Return on equity-23.0%-21.3%-33.4%
Current ratio27.5020.6923.29

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.